Anti-LDL Receptor - Biotinylated

LDL receptor (LDLR) is a cell surface glycoprotein that scavenges LDL from the blood and regulates plasma LDL levels. It is composed of an N-terminal signal sequence, a ligand-binding domain, an EGF precursor homology domain, an O-linked glycosylation domain, a transmembrane region, and a C-terminal cytoplasmic tail. LDLR is primarily expressed in the liver but is also found in the adrenal cortex. It mediates the endocytosis of LDL by binding to apolipoprotein E (ApoE) or ApoB on the LDL surface, thereby supplying cholesterol to cells. Protein levels of LDLR are decreased in HepG2 cells expressing proprotein convertase subtilisin kexin 9 (PCSK9). Knockout of Ldlr increases plasma levels of cholesterol and triglycerides and induces the formation of atherosclerotic lesions in mice. Mutations in LDLR are associated with familial hypercholesterolemia. Cayman's LDL Receptor Polyclonal Antibody - Biotinylated is composed of an LDLR polyclonal antibody conjugated to biotin and can be used for immunocytochemistry (ICC) and Western blot (WB) applications. This antibody recognizes LDLR at approximately 100 to 160 kDa from human, mouse, and rat samples.Synonyms: LDLR, Low Density Lipoprotein Receptor. Immunogen: Synthetic peptide from the C-terminal region of mouse LDLR. MW: ~100-160 kDa. Formulation: (Request formulation change), 50 µg of biotinylated IgG. Storage Buffer: PBS, pH 7.2, 50% glycerol, 0.1% BSA, and 0.02% sodium azide. Host: Rabbit. Applications: ICC, WB. Cross Reactivity: (+) LDLR. UniProt Accession #: P35951 (murine).